Holen Sie sich die Stockscreener-App
7.09
0.14%
0.010
Handel nachbörslich:
6.99
-0.10
-1.41%
Schlusskurs vom Vortag:
$7.08
Offen:
$7.16
24-Stunden-Volumen:
1.43M
Relative Volume:
0.70
Marktkapitalisierung:
$520.53M
Einnahmen:
$161.10M
Nettoeinkommen (Verlust:
$-308.60M
KGV:
-1.5182
EPS:
-4.67
Netto-Cashflow:
$-259.90M
1W Leistung:
+12.72%
1M Leistung:
-4.19%
6M Leistung:
-61.28%
1J Leistung:
-72.30%
1-Tages-Spanne:
$6.96
$7.26
1-Wochen-Bereich:
$6.32
$7.29
52-Wochen-Spanne:
$5.90
$29.61
Arvinas Inc Stock (ARVN) Company Profile
Firmenname
Arvinas Inc
Sektor
Branche
Telefon
203-535-1456
Adresse
395 WINCHESTER AVE, NEW HAVEN, CT
Vergleichen Sie ARVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
7.09 | 519.80M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-02 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | Herabstufung | Truist | Buy → Hold |
| 2025-05-02 | Herabstufung | Jefferies | Buy → Hold |
| 2025-05-02 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-03-13 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-12 | Herabstufung | Wedbush | Outperform → Neutral |
| 2025-03-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2024-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-01 | Eingeleitet | Goldman | Buy |
| 2023-12-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-11-20 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-10-23 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-01-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Eingeleitet | Barclays | Overweight |
| 2022-06-21 | Eingeleitet | Jefferies | Hold |
| 2022-05-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2022-01-19 | Eingeleitet | Goldman | Buy |
| 2021-12-07 | Eingeleitet | Cowen | Outperform |
| 2021-10-14 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-09 | Eingeleitet | BofA Securities | Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-21 | Eingeleitet | Truist | Buy |
| 2021-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-12-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-12 | Eingeleitet | Oppenheimer | Perform |
| 2019-12-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-25 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Hochstufung | Goldman | Neutral → Buy |
| 2019-09-25 | Eingeleitet | Wedbush | Outperform |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-08-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-22 | Eingeleitet | Citigroup | Buy |
| 2018-10-22 | Eingeleitet | Goldman | Neutral |
| 2018-10-22 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Arvinas Inc Aktie (ARVN) Neueste Nachrichten
Is Arvinas Inc. a speculative investmentMarket Movers & Daily Risk Controlled Trade Plans - thegnnews.com
FY2025 EPS Estimates for Arvinas Cut by Cantor Fitzgerald - MarketBeat
Can Arvinas Inc. scale operations efficientlyJuly 2025 Spike Watch & Free Safe Entry Trade Signal Reports - classian.co.kr
HC Wainwright Comments on Arvinas' Q3 Earnings (NASDAQ:ARVN) - MarketBeat
Leerink Partnrs Analysts Cut Earnings Estimates for Arvinas - MarketBeat
Wedbush Has Optimistic Outlook of Arvinas Q3 Earnings - MarketBeat
Will Arvinas Inc. stock go up soon2025 Retail Activity & High Accuracy Trade Signal Alerts - Newser
Will Arvinas Inc. stock benefit from AI tech trendsForecast Cut & Advanced Swing Trade Entry Plans - Newser
Arvinas’s SWOT analysis: protein degrader stock faces pivotal moment By Investing.com - Investing.com Nigeria
Arvinas’s SWOT analysis: protein degrader stock faces pivotal moment - Investing.com
How institutional ownership impacts Arvinas Inc. stockTake Profit & Daily Growth Stock Investment Tips - Newser
Arvinas, Inc. (NASDAQ:ARVN) Receives $19.76 Consensus PT from Analysts - MarketBeat
Custom watchlist performance reports with Arvinas Inc.Take Profit & Capital Efficiency Focused Ideas - Newser
Using data filters to optimize entry into Arvinas Inc.Fundamental + Technical Combined Watchlist - Newser
Arvinas (NASDAQ:ARVN) Given New $15.00 Price Target at Guggenheim - MarketBeat
Arvinas (NASDAQ:ARVN) Releases Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
HC Wainwright Has Lowered Expectations for Arvinas (NASDAQ:ARVN) Stock Price - MarketBeat
Is Arvinas Inc. Stock a Good Fit for Conservative InvestorsFree Real Time Stock Movement Analysis - Newser
Metastatic Prostate Cancer Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Merck Sharp & Dohme, Arvinas Androgen Receptor, UNICANCER, Aragon Pharma, Mark Stein, Novartis, Orion - Barchart.com
Pfizer and Arvinas' breast cancer therapy to be reviewed by FDA - MSN
FDA gives Arvinas and Pfizer’s vepdegestrant NDA for breast cancer - Yahoo Finance
Wedbush Issues Positive Forecast for Arvinas Earnings - Defense World
HC Wainwright Comments on Arvinas’ Q3 Earnings (NASDAQ:ARVN) - Defense World
Arvinas, Inc. (NASDAQ:ARVN) Shares Acquired by XTX Topco Ltd - MarketBeat
Wells Fargo & Company Cuts Arvinas (NASDAQ:ARVN) Price Target to $16.00 - Defense World
What Fibonacci levels say about Arvinas Inc. reboundSector Rotation Strategy for Smart Traders - Newser
Arvinas and Pfizer’s FDA Nod for Cancer Drug - The Globe and Mail
Arvinas, Inc. (NASDAQ:ARVN) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - 富途牛牛
Arvinas, Inc. (NASDAQ:ARVN) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance
FDA Accepts Arvinas, Pfizer's Vepdegestrant NDA for Breast Cancer Treatment - AInvest
FDA to Review Pfizer and Arvinas' Breast Cancer Therapy Vepdegestrant by June 5, 2026. - AInvest
Arvinas' Breakthrough in PROTACs: A Catalyst for Valuation Re-Rating in Oncology's New Frontier - AInvest
Arvinas Q2 2025 Earnings: Revenue Down, Clinical Progress & New CEO Announcement - AInvest
Arvinas, Pfizer announce FDA acceptance of vepdegestrant NDA - TipRanks
Arvinas and Pfizer Announce FDA Acceptance of NDA for Vepdegestrant Following Positive Phase 3 VERITAC-2 Trial Results in Advanced Breast Cancer - Quiver Quantitative
Arvinas Announces FDA Acceptance of the New Drug - GlobeNewswire
ARVNArvinas Latest Stock News & Market Updates - Stock Titan
Arvinas (NASDAQ:ARVN) Price Target Cut to $16.00 by Analysts at Wells Fargo & Company - MarketBeat
Arvinas Holding Company (ARVN) Gets a Buy from Guggenheim - The Globe and Mail
Arvinas Holding’s Strategic Uncertainties and Partnership Challenges Justify Hold Rating - TipRanks
A Quick Look at Today's Ratings for Arvinas(ARVN.US), With a Forecast Between $9 to $18 - 富途牛牛
Arvinas (ARVN) Shares Plunge 2.95% to 2025 Low Amid Mixed Clinical Results and Partnership Uncertainty - AInvest
Arvinas 2025 Q2 Earnings Record Net Income Despite Worsening Losses - AInvest
Arvinas, Pfizer reworking partnership on ‘Protac’ cancer drug - BioPharma Dive
Arvinas signals CEO transition and extends cash runway into H2 2028 amid vepdeg collaboration changes - MSN
Wall Street Has Mixed Opinions On Future Of Arvinas’ Investigational Drug: Retail’s Got A Cautious Approach - Stocktwits
Wedbush Cuts Price Target on Arvinas to $10 From $12, Keeps Neutral Rating - MarketScreener
Arvinas price target raised to $24 from $18 at H.C. Wainwright - TipRanks
Finanzdaten der Arvinas Inc-Aktie (ARVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):